July 30th 2021 EF Clif initiates the Global CHANCE study to analyze the benefit of liver transplantation among patients affected by Acute-on-Chronic Liver Failure EF Clif, in collaboration with ELITA and the International Liver Transplantation Society (ILTS), launched the CHANCE study: “Liver transplantation in patients with Cirrhosis and severe Acute-on-Chronic Liver Failure (ACLF): indications and outcomes, a multicenter and international three-year study, of a prospective and non-interventional observational nature”, in which over 2,000 patients from 95 hospitals located in 27 countries will be recruited.

The results obtained with the CHANCE study could contribute to the drafting of new protocols for clinical action for patients with different ACLF grades, improve the criteria for assigning organs to these patients, compare survival rates according to severity and establish the impact of liver transplantation on their quality of life.

Spain, together with the United Kingdom, are two of the countries that have recently introduced new recommendation that allow list ACLF as a priority indication for liver transplantation. A proposal by the Spanish Society of Liver Transplantation was published in Transplantation , which concluded that liver transplantation dramatically improves the prognosis in patients with ACLF. They drew up a consensus document introducing the EFCLIF criteria for ACLF so that liver transplantation can be expanded homogeneously in Spain. “Every year around one million people with ACLF die in Europe. Several studies carried out so far have shown that liver transplantation is an option that clearly improves the survival of these patients. The results of the global CHANCE study will be important to better define criteria for selection, make transplantation even safer and allow harmonisation across the world”, says Rajiv Jalan, Scientific Director of EF Clif. On July 7 2021, the Italian Hospital in Buenos Aires, Argentina included the first patient in the CHANCE study. We congratulate the team of Dr Marciano and Gadano, who have led the way to the inclusion.